Scarica l'app Stockscreener
1.77
15.71%
-0.33
Precedente Chiudi:
$2.10
Aprire:
$2.1
Volume 24 ore:
1.28M
Relative Volume:
2.34
Capitalizzazione di mercato:
$186.46M
Reddito:
$7.05M
Utile/perdita netta:
$-30.43M
Rapporto P/E:
-4.6727
EPS:
-0.3788
Flusso di cassa netto:
$21.84M
1 W Prestazione:
-11.06%
1M Prestazione:
-23.71%
6M Prestazione:
-23.04%
1 anno Prestazione:
-32.44%
Intervallo 1D:
$1.74
$2.12
Intervallo di 1 settimana:
$1.74
$2.275
Portata 52W:
$1.07
$3.10
Proqr Therapeutics N V Stock (PRQR) Company Profile
Nome
Proqr Therapeutics N V
Settore
Industria
Telefono
-
Indirizzo
-
Confronta PRQR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.77 | 221.22M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-29 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-04-29 | Iniziato | Evercore ISI | Outperform |
| 2025-03-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-01-10 | Iniziato | Oppenheimer | Outperform |
| 2024-10-29 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2022-02-11 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | Downgrade | Stifel | Buy → Hold |
| 2022-02-01 | Iniziato | Raymond James | Strong Buy |
| 2021-05-03 | Iniziato | Stifel | Buy |
| 2021-03-25 | Reiterato | Citigroup | Buy |
| 2020-11-03 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-03-12 | Reiterato | Chardan Capital Markets | Buy |
| 2018-12-19 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-11-15 | Iniziato | Citigroup | Buy |
| 2018-09-19 | Iniziato | Evercore ISI | Outperform |
| 2017-09-26 | Reiterato | JMP Securities | Mkt Outperform |
| 2016-06-20 | Iniziato | Chardan Capital Markets | Neutral |
| 2014-10-15 | Iniziato | Deutsche Bank | Buy |
| 2014-10-13 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Proqr Therapeutics N V Borsa (PRQR) Ultime notizie
Why ProQR Therapeutics N.V. (0PQ) stock stays undervalued2025 Price Momentum & Weekly Stock Breakout Alerts - ulpravda.ru
Why ProQR Therapeutics N.V. stock is a value investor pick2025 Pullback Review & Risk Adjusted Swing Trade Ideas - ulpravda.ru
ProQR stock falls after initial AX-0810 data, pipeline updates By Investing.com - Investing.com Australia
ProQR Reports Positive AX-0810 Phase 1 Data, Advances Rett and MASH Candidates, and Outlines 2026 Pipeline Plans - TipRanks
ProQR reports positive initial AX-0810 safety data in phase 1 trial - Investing.com India
ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook - Yahoo Finance
ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Below 50 Day Moving AverageHere's What Happened - MarketBeat
Why ProQR Therapeutics N.V. stock is considered a top pickCapital Gains Strategies & Create Passive Income With Smart Stocks - ulpravda.ru
ProQR Therapeutics N.V. (PRQR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below 50-Day Moving AverageHere's What Happened - MarketBeat
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) top owners are individual investors with 34% stake, while 29% is held by institutions - Yahoo Finance
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Can ProQR Therapeutics N.V. (0PQ) stock sustain double digit ROEJuly 2025 Review & Free Technical Confirmation Trade Alerts - Улправда
Can ProQR Therapeutics N.V. stock sustain market leadershipEarnings Date Calendar & Fast Profit Trading Strategies - Bollywood Helpline
How ProQR Therapeutics N.V. (0PQ) stock gains from tech spendingWeekly Gains Summary & Long-Term Safe Investment Ideas - Улправда
Can ProQR Therapeutics N.V. stock hit analyst price targetsJuly 2025 Macro Moves & Weekly Setup with ROI Potential - Улправда
Is ProQR Therapeutics N.V. stock a safe haven assetJuly 2025 Catalysts & Weekly Breakout Watchlists - Улправда
Will ProQR Therapeutics N.V. stock maintain momentum in 20252025 Key Highlights & Community Consensus Picks - Улправда
Breakout Zone: Why ProQR Therapeutics N.V. (0PQ) stock stays undervaluedWeekly Stock Summary & Low Risk High Reward Trade Ideas - Улправда
Will ProQR Therapeutics N.V. (0PQ) stock justify high valuationTrade Analysis Summary & Long-Term Growth Portfolio Plans - Улправда
Bull Run: Is ProQR Therapeutics N.V. stock a buy in volatile marketsMarket Trend Review & Real-Time Volume Analysis - Улправда
Can ProQR Therapeutics N.V. stock sustain free cash flow growthJuly 2025 Earnings & Fast Moving Trade Plans - Улправда
Is ProQR Therapeutics N.V. (0PQ) stock nearing a technical breakoutTrade Volume Report & AI Powered Trade Plan Recommendations - DonanımHaber
ProQR Therapeutics N.V PRQR’s stock price falss traction on Friday - uspostnews.com
Ready to Jump After Recent Trade: ProQR Therapeutics N.V (PRQR) - setenews.com
Is ProQR Therapeutics NV 0PQ a good long term investmentDividend Stock Watch & Free Unlock Stock Analysis - earlytimes.in
Is ProQR Therapeutics N.V. (0PQ) stock a good hedge against inflationWeekly Trade Analysis & Proven Capital Preservation Tips - Newser
Is ProQR Therapeutics N.V. (0PQ) stock a buy during volatile marketsCPI Data & Weekly Top Performers Watchlists - Newser
Will ProQR Therapeutics N.V. (0PQ) stock enhance shareholder value2025 Valuation Update & Long-Term Growth Stock Strategies - Newser
ProQR Therapeutics N.V. (PRQR) 5.47% in After-hours: Gains Ahead of Healthcare Conference - Stocks Telegraph
A look into ProQR Therapeutics N.V (PRQR)’s deeper side - setenews.com
Can ProQR Therapeutics N.V. (0PQ) stock surprise with quarterly results2025 Market Sentiment & Growth Focused Investment Plans - Newser
ProQR Therapeutics (PRQR) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Can ProQR Therapeutics N.V. (0PQ) stock ride next bull market cycleJuly 2025 Short Interest & AI Powered Buy and Sell Recommendations - Newser
How ProQR Therapeutics N.V. (0PQ) stock valuation compares with sectorQuarterly Portfolio Report & Safe Capital Growth Tips - Newser
Why ProQR Therapeutics N.V. (0PQ) stock is a strong buy callMarket Risk Report & Smart Allocation Stock Tips - Newser
How ProQR Therapeutics N.V. (0PQ) stock compares with tech leaders2025 Historical Comparison & Weekly Setup with High ROI Potential - Newser
Is ProQR Therapeutics N.V. stock attractive for hedge funds2025 Big Picture & Accurate Entry and Exit Point Alerts - Newser
ProQR Therapeutics N.V. to Participate in 8th Annual Evercore Healthcare Conference on December 4, 2025 - Quiver Quantitative
ProQR to Participate in 8th Annual Evercore Healthcare Conference - GlobeNewswire Inc.
How ProQR Therapeutics N.V. stock benefits from global expansionQuarterly Investment Review & Comprehensive Market Scan Reports - BỘ NỘI VỤ
Taking on analysts’ expectations and winning: ProQR Therapeutics N.V (PRQR) - setenews.com
Activity Recap: Why ProQR Therapeutics N.V. stock is a value investor pickJuly 2025 Volume & Capital Protection Trade Alerts - moha.gov.vn
ProQR Therapeutics NV Stock Analysis and ForecastVWAP Trading Strategies & Market Trend Real-Time Reports - earlytimes.in
Whale Trades: Why ProQR Therapeutics N.V. stock is considered a top pick2025 Market WrapUp & Community Consensus Picks - moha.gov.vn
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Proqr Therapeutics N V Azioni (PRQR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):